Biosimilars Market Size, Share, Trends & Competitive Analysis By Product Type (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides, Others); By Therapeutic Application (Oncology, Autoimmune Diseases, Blood Disorders, Infectious Diseases, Growth Hormone Deficiency, Others) By Manufacturing Process; By Distribution Channel: By End User: By Regions, and Industry Forecast, Global Report 2023-2030

The global Biosimilars Market size was valued at USD 26.8 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 19.4% during the forecast period, reaching a value of USD 88.05 billion by 2030.

Biosimilars Market research report by Future Data Stats, offers a comprehensive view of the market's historical data from 2017 to 2021, capturing trends, growth patterns, and key drivers. It establishes 2021 as the base year, analyzing the market landscape, consumer behavior, competition, and regulations. Additionally, the report presents a well-researched forecast period from 2022 to 2030, leveraging data analysis techniques to project the market's growth trajectory, emerging opportunities, and anticipated challenges.


Biosimilars are a class of biological products that are highly similar to and have no clinically meaningful differences from approved reference biologic medicines. They are designed to offer affordable alternatives to expensive originator biologics, providing patients with increased access to vital treatments. Biosimilars are developed through a rigorous scientific process that involves demonstrating similarity in terms of quality, safety, and efficacy to the reference product.

Market research in the field of Biosimilars aims to assess market potential, identify key market players, analyze regulatory landscapes, evaluate pricing and reimbursement policies, and understand market dynamics and opportunities for growth. Understanding the market landscape and trends surrounding Biosimilars is crucial for stakeholders to make informed decisions and capitalize on the expanding opportunities in this evolving market segment.


Firstly, the rising prevalence of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has created a significant demand for cost-effective treatment options. Biosimilars offer a more affordable alternative to expensive biologic drugs, making them accessible to a larger patient population. Secondly, stringent regulatory frameworks and patent expirations of biologic drugs have opened up opportunities for biosimilar manufacturers to enter the market. With the growing emphasis on reducing healthcare costs, governments and healthcare organizations are actively promoting the adoption of biosimilars, further driving market growth.

However, the Biosimilars market also faces certain restraints. Intellectual property rights and complex regulatory processes pose significant challenges for manufacturers in obtaining approvals and launching biosimilar products. Moreover, the high development costs associated with biosimilar manufacturing and the need for extensive clinical trials to demonstrate similarity to reference products can hinder market growth. Additionally, safety concerns and the perception that biosimilars may not be as efficacious as the originator biologics could impact consumer acceptance and adoption.

Nevertheless, the Biosimilars market presents promising opportunities. The increasing number of biologic drugs going off-patent in the coming years creates a favorable environment for biosimilar manufacturers to expand their product portfolios and gain market share. Moreover, the growing acceptance and confidence in biosimilars among healthcare professionals, regulatory bodies, and payers are likely to drive market growth. Strategic collaborations and partnerships between biosimilar manufacturers and key market players can also unlock new opportunities, facilitating market expansion and market penetration into untapped regions.



Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides, and other product categories play a crucial role in shaping the market dynamics. These diverse product types cater to various therapeutic applications and patient needs, offering a wide range of treatment options.

Recombinant Non-Glycosylated Proteins, such as insulin and growth factors, are witnessing significant demand due to their effectiveness in treating conditions like diabetes and growth hormone deficiency. Similarly, Recombinant Glycosylated Proteins, including monoclonal antibodies, are extensively used in oncology and autoimmune disease treatments. Additionally, Recombinant Peptides are gaining prominence in managing conditions such as hormone imbalances and metabolic disorders. The presence of other product categories further contributes to the market's versatility, providing innovative solutions for unmet medical needs.


Therapeutic areas such as Oncology, Autoimmune Diseases, Blood Disorders, Infectious Diseases, Growth Hormone Deficiency, and others play a pivotal role in shaping the market landscape. The prevalence of these medical conditions and the need for effective and affordable treatment options drive the demand for Biosimilars in each therapeutic category.

Oncology, being one of the largest segments, sees a high demand for Biosimilars due to the increasing incidence of cancer and the rising cost of biologic cancer treatments. Similarly, Biosimilars targeting autoimmune diseases, such as rheumatoid arthritis and psoriasis, provide cost-effective alternatives to biologics, expanding patient access to these critical therapies. Blood disorders, including anemia and hemophilia, also offer substantial opportunities for Biosimilar manufacturers to address the unmet medical needs in this field.


The two primary manufacturing processes in focus are Mammalian Cell Culture and Microbial Fermentation, with other manufacturing methods also playing a role. These manufacturing processes are crucial determinants of the quality, scalability, and cost-effectiveness of Biosimilars production.

Mammalian Cell Culture is a widely adopted manufacturing process, particularly for complex biologic products. It involves using mammalian cell lines to produce biosimilars that closely resemble the structure and function of the reference biologics. This process offers high protein expression levels and ensures proper post-translational modifications, making it suitable for developing Biosimilars with glycosylated proteins and other complex molecules. On the other hand, Microbial Fermentation involves using microbial cells, such as bacteria or yeast, to produce biosimilars. This process is often employed for biosimilars with non-glycosylated proteins and peptides, offering cost and time advantages.


Hospital Pharmacies serve as an important distribution channel, particularly for Biosimilars used in hospital settings and specialty care. They have established relationships with healthcare facilities, enabling direct access to physicians, nurses, and patients. Retail Pharmacies, on the other hand, cater to a broader patient population, providing Biosimilars in community-based settings. These pharmacies offer convenience and accessibility, allowing patients to obtain Biosimilars closer to their homes.

The rise of digital platforms has also led to the emergence of Online Pharmacies as a prominent distribution channel for Biosimilars. Online Pharmacies provide the convenience of home delivery and a wider range of products, attracting patients seeking cost-effective alternatives. Market research in this area focuses on analyzing the market share and growth potential of each distribution channel, understanding patient preferences, and assessing factors such as regulatory compliance, supply chain efficiency, and pricing strategies. Such insights help stakeholders in developing targeted distribution strategies, optimizing reach, and maximizing market penetration for Biosimilars in different healthcare settings.


Hospitals are a major end user of Biosimilars, as they provide a wide range of medical services and treatments to patients. The adoption of Biosimilars in hospitals is driven by the need to manage healthcare costs while ensuring high-quality care. Clinics, including specialty clinics and outpatient centers, also contribute significantly to the demand for Biosimilars. These settings often focus on specific therapeutic areas and provide targeted treatments, making Biosimilars an attractive option due to their cost-effectiveness.

Research Institutes play a vital role in advancing scientific knowledge and conducting clinical trials related to Biosimilars. These institutions often collaborate with biosimilar manufacturers to evaluate safety, efficacy, and comparative effectiveness of Biosimilars, contributing to market growth. Other healthcare facilities, such as long-term care centers and rehabilitation centers, also present opportunities for Biosimilar adoption, especially for specific indications and patient populations.


North America, comprising the United States and Canada, has been a prominent market for Biosimilars, driven by supportive regulatory pathways, the presence of well-established biopharmaceutical companies, and the need to address rising healthcare costs. Europe has also emerged as a key market, with countries like Germany, France, and the United Kingdom at the forefront of Biosimilar adoption. The European Medicines Agency (EMA) has implemented a robust regulatory framework, fostering a competitive market environment.

Asia Pacific offers immense growth potential in the Biosimilars market, driven by the increasing prevalence of chronic diseases, improving healthcare infrastructure, and a strong emphasis on cost-effective treatments. Countries such as India and South Korea have emerged as major players in Biosimilar manufacturing, catering to both domestic and international markets. Latin America and the Middle East and Africa regions are also witnessing a gradual uptake of Biosimilars, driven by improving healthcare access, increasing awareness, and government initiatives to promote affordable healthcare options.


The pandemic has led to disruptions in the supply chain, manufacturing processes, and distribution networks of Biosimilars. Lockdown measures, travel restrictions, and temporary closures of manufacturing facilities have affected the production and availability of Biosimilars. Furthermore, healthcare resources and attention have been diverted towards managing COVID-19 patients, impacting the adoption and uptake of Biosimilars in some regions.

However, the pandemic has also highlighted the need for cost-effective treatments, driving the demand for Biosimilars in certain therapeutic areas. As healthcare systems face financial constraints, Biosimilars offer a more affordable alternative to expensive biologic drugs, making them an attractive option for healthcare providers and payers. Additionally, the pandemic has accelerated the adoption of telemedicine and digital health platforms, creating new opportunities for the promotion and distribution of Biosimilars through online channels.


Mergers & Acquisitions:

  • Biocon Biologics acquired Viatris' global biosimilars business for $3 billion in 2022
  • Fresenius Kabi acquired an initial 55% stake in Insud Pharma's biopharma unit, mAbxience in 2022
  • Samsung Bioepis acquired Celltrion's biosimilars business in Europe in 2023
  • Pfizer acquired Affinivax, a developer of next-generation pneumococcal vaccines in 2023

Product New Launches:

  • Rezvoglar (insulin glargine) and Cimerli (ranibizumab) were designated as interchangeable biosimilars by the FDA. in 2022
  • Amgen launched AMJEVITA (adalimumab-atto), a biosimilar to Humira in 2022
  • Sandoz launched Zarxio (filgrastim-sndz), a biosimilar to Neupogen in 2023
  • Teva launched Tevagra (pegfilgrastim-tev), a biosimilar to Neulasta in 2023


  • Pfizer Inc.
  • Sandoz International GmbH (Novartis AG)
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Inc.
  • Samsung Bioepis Co., Ltd.
  • Amgen Inc.
  • Biocon Ltd.
  • Mylan N.V.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Biogen Inc.
  • Fresenius Kabi AG
  • Amneal Pharmaceuticals LLC
  • Stada Arzneimittel AG
  • Accord Healthcare Ltd.
  • Lupin Limited
  • Sanofi S.A.
  • Eli Lilly and Company
  • Cipla Ltd.
  • Apotex Inc.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila Healthcare Ltd.
  • Hospira Inc. (Pfizer Inc.)

Table of Contents

  1. Executive Summary

    • Overview of the Biosimilars Market
    • Key Findings
    • Market Highlights
  2. Introduction

    • Market Definition
    • Market Segmentation
    • Research Methodology
  3. Market Dynamics

    • Drivers
    • Restraints
    • Opportunities
    • Challenges
  4. Regulatory Landscape

    • Regulatory Pathways for Biosimilars
    • Key Regulatory Bodies and Guidelines
  5. Market Analysis

    • Market Size and Forecast
    • Market Trends and Insights
    • Porter's Five Forces Analysis
    • SWOT Analysis
  6. Product Type Analysis

    • Recombinant Non-Glycosylated Proteins
    • Recombinant Glycosylated Proteins
    • Recombinant Peptides
    • Others
  7. Therapeutic Application Analysis

    • Oncology
    • Autoimmune Diseases
    • Blood Disorders
    • Infectious Diseases
    • Growth Hormone Deficiency
    • Others
  8. Manufacturing Process Analysis

    • Mammalian Cell Culture
    • Microbial Fermentation
    • Others
  9. Distribution Channel Analysis

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  10. End User Analysis

    • Hospitals
    • Clinics
    • Research Institutes
    • Others
  11. Regional Analysis

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  12. Competitive Landscape

    • Key Market Players
    • Market Share Analysis
    • Mergers and Acquisitions
    • Product Launches
  13. Pricing and Reimbursement Analysis

    • Government Regulations
    • Insurance Coverage
    • Pricing Strategies
  14. Case Studies

  15. Future Outlook and Market Opportunities

  16. Conclusion


By Product Type:

  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Recombinant Peptides
  • Others

By Therapeutic Application:

  • Oncology
  • Autoimmune Diseases
  • Blood Disorders
  • Infectious Diseases
  • Growth Hormone Deficiency
  • Others

By Manufacturing Process:

  • Mammalian Cell Culture
  • Microbial Fermentation
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User:

  • Hospitals
  • Clinics
  • Research Institutes
  • Others


By Geography:

  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Reasons to Buy this Report

  • Comprehensive Insights: Market research reports provide in-depth and comprehensive insights into various industries, markets, and sectors. These reports are prepared after extensive data collection, analysis, and interpretation, offering you valuable information and a clear understanding of market trends, dynamics, and opportunities.
  • Future Predictions: Market research reports often include future data statistics, forecasts, and predictions. These predictions are based on rigorous analysis and modeling techniques, taking into account various factors such as market growth drivers, challenges, and emerging trends. By accessing these future data stats, you can make informed decisions and develop strategies that align with the projected market scenarios.
  • Industry Analysis: Market research reports offer detailed industry analysis, including factors such as market size, market share, competitive landscape, and key players. These reports provide an overview of the industry's current status, growth potential, and competitive dynamics, enabling you to identify lucrative opportunities and stay ahead of the competition.
  • Market Trends and Opportunities: By purchasing market research reports, you gain access to up-to-date information on market trends and emerging opportunities. These reports highlight the latest consumer preferences, technological advancements, regulatory changes, and other influential factors shaping the market landscape. Keeping track of these trends helps you identify potential growth areas and adapt your business strategies accordingly.
  • Risk Mitigation: Investing in a market research report can help mitigate risks associated with market uncertainties. The reports provide insights into potential risks, challenges, and barriers to entry in specific markets or industries. With this knowledge, you can develop risk mitigation strategies, anticipate market fluctuations, and make informed decisions to minimize potential losses.
  • Investment Decision Support: Market research reports are valuable tools for investors, venture capitalists, and financial institutions. These reports provide reliable and data-driven information that aids in investment decision-making processes. By analyzing market research reports, investors can evaluate the market potential, assess the feasibility of investment opportunities, and gauge the expected returns on investment.
  • Product Development and Innovation: Market research reports offer insights into consumer preferences, needs, and demands. This information can be leveraged for product development and innovation. By understanding the market dynamics and consumer behavior, you can tailor your products or services to meet the evolving needs of your target audience, leading to enhanced customer satisfaction and market success.
  • Strategic Planning: Market research reports serve as a foundation for strategic planning. They provide a comprehensive overview of the market landscape, competitive positioning, and growth potential. With this knowledge, you can develop effective business strategies, set realistic goals, and allocate resources efficiently. Strategic planning based on accurate market research helps optimize your operations and improve your chances of success.
  • Market Entry and Expansion: For businesses looking to enter new markets or expand their existing operations, market research reports are indispensable. These reports provide insights into market dynamics, consumer behavior, regulatory frameworks, and competitive landscapes specific to the target markets. This information helps you assess the feasibility of market entry, identify potential obstacles, and develop market entry strategies that increase your chances of success.
  • Evidence-Based Decision Making: Market research reports provide evidence-based data and analysis, enabling you to make informed decisions. Rather than relying on assumptions or guesswork, you can base your decisions on reliable information and market insights. Evidence-based decision making reduces the risk of costly mistakes and increases the likelihood of achieving your business objectives.


With a collective industry experience of about 70 years of analysts and experts, Future Data Stats encompasses the most infallible research methodology for its market intelligence and industry analysis. Not only does the company dig deep into the innermost levels of the market, but also examines the minutest details for its market estimates and forecasts.

This approach helps build a greater market-specific view of size, shape, and industry trends within each industry segment. Various industry trends and real-time developments are factored into identifying key growth factors and the future course of the market. The research proceeds are the results of high-quality data, expert views & analysis, and valuable independent opinions. The research process is designed to deliver a balanced view of the global markets and allows stakeholders to make informed decisions, to attain their highest growth objectives.

Future Data Stats offers its clients exhaustive research and analysis, based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models distill the data & statistics and enhance the accuracy of our recommendations and advice.

With Future Data Stats calibrated research process and 360° data-evaluation methodology, the clients receive:

  • Consistent, valuable, robust, and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through a well-audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of the marketplace

With this strong methodology, Future Data Stats ensures that its research and analysis is most reliable and guarantees sound business planning.

The research methodology of the global market involves extensive primary and secondary research. Primary research includes about 24 hours of interviews and discussions with a wide range of stakeholders that include upstream and downstream participants. Primary research typically is a bulk of our research efforts, coherently supported by extensive secondary research. Over 3000 product literature, industry releases, annual reports, and other such documents of key industry participants have been reviewed to obtain a better market understanding and gain enhanced competitive intelligence. In addition, authentic industry journals, trade associations’ releases, and government websites have also been reviewed to generate high-value industry insights.

Primary Research:

Primary Research


Desk Research


Company Analysis


•       Identify key opinion leaders

•       Questionnaire design

•       In-depth Interviews

•       Coverage across the value chain


•       Company Website

•       Company Annual Reports

•       Paid Databases

•       Financial Reports


•       Market Participants

•       Key Strengths

•       Product Portfolio

•       Mapping as per Value Chain

•       Key focus segment


Primary research efforts include reaching out to participants through emails, telephonic conversations, referrals, and professional corporate relations with various companies that make way for greater flexibility in reaching out to industry participants and commentators for interviews and discussions.

The aforementioned helps to:

  • Validate and improve data quality and strengthen the research proceeds
  • Develop a market understanding and expertise
  • Supply authentic information about the market size, share, growth, and forecasts

The primary research interview and discussion panels comprise experienced industry personnel.

These participants include, but are not limited to:

  • Chief executives and VPs of leading corporations specific to an industry
  • Product and sales managers or country heads; channel partners & top-level distributors; banking, investments, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research:

A broad array of industry sources for the secondary research typically includes, but is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor  presentations for a competitive scenario and shape of the industry
  • Patent and regulatory databases to understand technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles, web-casts, and other related releases to evaluate the market
  • Internal and external proprietary databases, key market indicators, and relevant press releases for  market estimates and forecasts



•       Top executives of end-use industries

•       C-level executives of the leading Parenteral Nutrition companies

•       Sales manager and regional sales manager of the Parenteral Nutrition companies

•       Industry Consultants

•       Distributors/Suppliers


•       Annual Reports

•       Presentations

•       Company Websites

•       Press Releases

•       News Articles

•       Government Agencies’ Publications

•       Industry Publications

•       Paid Databases


Analyst Tools and Models:



·         Arriving at
Global Market Size

·         Arriving at
Market Size

·         Market Share
of Key Players

·         Key Market Players

·         Key Market Players

·         Market Share
of Key Players

·         Arriving at
Market Size

·         Arriving at
Global Market Size


will update soon

Frequently Asked Questions

The global Biosimilars Market size was valued at USD 26.8 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 19.4% during the forecast period, reaching a value of USD 88.05 billion by 2030.

The rising prevalence of chronic diseases, increasing demand for cost-effective treatments, patent expirations of reference biologics, favorable regulatory pathways, and the need to address healthcare affordability and accessibility.

The development of biosimilars for a wide range of therapeutic applications, advancements in manufacturing processes, increasing collaborations and partnerships among industry players, adoption of advanced analytical techniques for similarity assessment, and the integration of digital health technologies for distribution and patient monitoring.

North America and Europe have established regulatory frameworks and a strong focus on cost containment in healthcare. Asia Pacific is witnessing significant growth due to increasing healthcare expenditure, a large patient population, and favorable government initiatives.

The stringent regulatory requirements, intellectual property issues, safety concerns, and the need for extensive clinical trials. However, opportunities lie in the growing demand for affordable biologic therapies, market expansion in developing regions, strategic collaborations, and advancements in manufacturing technologies.
Why Future Data Stats?
Examine Of Marketplace

Your Commercial Enterprise Can Develop Primarily Based On Exclusive Research Results, Along Side Insightful Services. It's Going To Also Allow You To Recognize Diverse Marketing Updates And Different Brand In A Extra Efficient Way.

1+ Million Marketplace Research Report

we performs all the essential studies and provide commonly accurate, result oriented income statistics, market facts, and data marketplace scenarios of the past and future. with experience of over 10 years our research report library cover collection of one million plus reports.

Prediction about the Worldwide Marketplace

so as to gain information on the worldwide markets future data stats offer most correct market prediction using both pessimistic view to benefit truthful concept of future development.

Traditional and Hybrid Methodologies

future data stats presents a holistic and extra accurate view of the marketplace through a aggregate of secondary and primary research and hybrid methodologies.